The story of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated massive gains, the lapse of its patent opened the door to generic versions, dramatically reducing https://bookmarkgenious.com/story21777533/the-copyright-and-the-pharmaceutical-industry-a-volatile-bet